Application of radioactive 131I in the treatment of Graves disease

Wu Chenchenoverview; Zhang Xiaomeiproofreading

Journal of Bengbu Medical University > 2014 > 38(5): 697-700.

Wu Chenchenoverview, Zhang Xiaomeiproofreading. Application of radioactive 131I in the treatment of Graves disease[J]. Journal of Bengbu Medical University, 2014, 38(5): 697-700.

Citation:

Wu Chenchenoverview, Zhang Xiaomeiproofreading. Application of radioactive 131I in the treatment of Graves disease[J]. Journal of Bengbu Medical University, 2014, 38(5): 697-700.

Citation:

Wu Chenchenoverview, Zhang Xiaomeiproofreading. Application of radioactive 131I in the treatment of Graves disease[J]. Journal of Bengbu Medical University, 2014, 38(5): 697-700.

Application of radioactive 131I in the treatment of Graves disease

Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical College, Anhui Bengbu 233004

More Information

Received Date: May 26, 2012

Graphical Abstract

Abstract

Abstract

Graves disease is the cause of hyperthyroidism (Graves) is the most common disease, hyperthyroidism patients accounted for 80% ~ 85%, it is suggested that the occurrence of associated with autoimmune, belongs to the field of organ specific autoimmune diseases
- Graves disease,
- iodine,
- review

FullText(HTML)

References (52)

References

[1]	滕卫平.甲状腺功能亢进症[M]//陆再英.内科学.7版.北京:人民卫生出版社,2008:712-721.
[1]	[2] Singer PA，Cooper DS，Levy EC，et al.Treatment guidelines for patients with hyperthyroidism and hypothyroidism.Standards of Care Committee,American Thyroid Association[J].JAMA，1995，273(10)：808-812.
[2]	[3] Arbelle JE，Porath A.Practice guidelines for the detection and management of thyroid dysfunction.A comparative review of the reconunendations[J].Clin Endocdnol，1999，51(1)：11-18.
[3]	[4] Wartofsky L.Radioiodine therapy for Graves' disease:case selection and restrictions recommended to patients in North America[J].Thyroid，1997，7(2)：213-216.
[4]	[5] Nygaard B，Hegedtis L，Gervil M，et al.Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism i n Graves' disease[J].J Intern Med，1995,238(6):491-497.
[5]	[6] Read CH Jr,Tansey MJ.Menda Y.A 36-yeat retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients[J].J Clin Endocrinol Metab,2004,89(9):4229-4233.
[6]	[7] Moll GW Jr,Patel BR.Pediatric Graves disease therapeutic options and experience with radioiodline at the University of Miss-sissippi Medical Center[J].South Med J,1997,90(10):1017-1022.
[7]	[8] 中华医学会内分泌学分会.中国甲状腺疾病诊治指南2甲状腺功能亢进症[J].中华内科杂志,2007,55(10):876-883.
[8]	[9] 白耀.甲状腺病学：基础与临床[M].北京：科学技术文献出版社，2003:390-392.
[9]	[10] 李梅，邱明才，李欣，等.Graves病合并白细胞减少患者血清对骨髓细胞粒-单核细胞系集落形成单位生长的影响[J].中华医学杂志，2002，82(9):643-645.
[10]	[11] 谭天秩.临床核医学[M].2版.北京：科学技术出版社，2003：1218 -1250.
[11]	[12] 赵红莉.131I治疗甲亢伴白细胞减少28例临床观察[J].湖南中医药大学学报，2011,31(6)：35-36.
[12]	[13] 康志强.131I治疗甲亢伴白细胞减少26例分析[J].中国误诊学杂志，2007，7(3)：594- 595.
[13]	[14] Singer PA，Cooper DS，Levy EJ，et al.Treatment guidelines for patients with hyperthyroidism and hypothyroidism[J].JAMA，1995，273(10)：808-812.
[14]	[15] 邢家骝.131I治疗良性甲状腺病的进展[J].中华内分泌代谢杂志，2001，17(4)：259-261.
[15]	[16] Read CJ，Tansey MJ，Menda Y.A 36-year retrospective analysis of The efficacy an d safety of radioactive iodine in treating young Graves patients[J].J Clin Endocrinol Metab，2004，89(9)：4229-4233.
[16]	[17] 陈丹云，陈棠华.131I与抗甲状腺药物治疗儿童Grave病的疗效对照研究[J].中华儿科杂志，2005，43(5)：507-509.
[17]	[18] Perros P,Kendall-Taylor P.Pathogenetic mechanisms in thyroid-associated ophthalmopathy [J].Clin Endocrinol,1992,231(3):205-211.
[18]	[19] 宋补昌,李宝兰,孙斌.血清TRAb检测对Graves病突眼的应用价值[J].放射免疫学杂志,2005,18(1):478-479.
[19]	[20] 刘子英.131I治疗甲亢合并突眼症1 269例疗效分析[J].中华核医学杂志，2007，28(1)：10-11.
[20]	[21] 肖茜,谭建,张桂芝,等.131I治疗后Graves病突眼与甲亢病情转归相关分析[J].山东医药,2010,50(17):3-4.
[21]	[22] 修喜龙，关丽.131I治疗甲亢性心脏病106例分析[J].中国地方病预防杂志，2005,20(3)：190.
[22]	[23] Kinugawa K，Yonekura K，Ribeiro RC，et al.Regulationof thyroid hormone receptor isoforms in physiologicaland pathological cardiac hypertrophy[J].Circ Res，2001，89(7)：591-598.
[23]	[24] Pantos C，Malliopoulou V，Varonos DD，et al.Thyroid hormone and phenotypes of cardioprotection[J].Basic Res Cardiol，2004，99(2)：101-102.
[24]	[25] Venditti P，De Rosa R，Cigliano L，et al.Role of nitric oxide in the functional to ische mia-reperfusion of heart mitochondriafrom hyperthyroid rats[J].Cell Mol Life Sci，2004，61(17)：2244-2252.
[25]	[26] 陆再英，钟南山.内科学[M].北京：人民卫生出版社，2008：714.
[26]	[27] 谢基龙.甲亢性心脏病189例临床分析[J].现代诊断与治疗，2005,16(3)：178.
[27]	[28] 赵明,田爱娟,季晓鹏,等.放射性131I治疗甲亢性心脏病的临床价值[J].中国医药,2009,4(11):862-863.
[28]	[29] 王勤奋，张承刚，赵晓斌，等.1 003例Graves病131I临床分析[J].中华核医学杂志，2005，25(2)：108-110.
[29]	[30] Traino AC,Grosso M,Mariani G.Possibility of limiting the unjustified irradiation in 131I therepy of Graves' diease:a thyroid mass-reduction based method for the optimum activity calculation [J].Phys Med,2010,26(2):71-79.
[30]	[31] 武忠弼.病理学[M].4版.北京：人民卫生出版社,2001:411.
[31]	[32] 马寄晓，刘秀杰.实用临床核医学[M].北京：原子能出版社，1990:341.
[32]	[33] 张灌生.甲状腺体积简易检测方法的研究[J].中国超声医学杂志，1998，14(5)：48.
[33]	[34] 顾光官，邹新农,王心涛，等.CT测定甲状腺体积(重量)的研究及临床应用[J].临床放射学杂志，1998，17(2)：84.
[34]	[35] 周新建,魏来,杨晓晖.131I治疗Graves病疗效及影响因素分析[J].中国医药导报,2008,5(18):18-19.
[35]	[36] Liu CJ,Dong YY,Wang YW,et al.Efficiency analysis of using tailored individual does of radioiodine of fine tuning using a lowdose antithyroid drug in the treatment of Graves' diease[J].Nucl Med Commun,2011,32(3):227-232.
[36]	[37] 刘剑锋，张友仁.131I治疗甲亢后早发甲减的临床分析[J].中华核医学杂志，2004,24(4)：245-246
[37]	[38] 张承刚.甲状腺疾病核素治疗学[M].北京：原子能出版社，2003：12.
[38]	[39] 高慧，施秉银，马秀萍，等.现代甲状腺疾病诊断与治疗[M].西安：陕西科学技术出版社，1998：196.
[39]	[40] Bringmann IM，Van Leeuwen BI,Hennemann G，et al.Outcome of treatment of hyperthyroidism[J].J Endocrinol Invest，1999，22(4)：250-256.
[40]	[41] 李林，廖嘉，赵豫琴.Graves患者131I治疗前后TGAb、TMAb与TPOAb水平变化及其临床观察[J].标记免疫分析与临床，2006，13(4)：213-214.
[41]	[42] 刘超，张忠邦.甲状腺特异性抗体[J].中华内分泌代谢杂志，1994,10(1):28-30.
[42]	[43] 郑向红，陈炜，王社教，等.成人原发性甲状腺功能减退症患者治疗前后脑血流灌注显像比较[J].中国医学影像技术，2010，26(9)：1751-1754.
[43]	[44] Goldman L，Bennett P.西氏内科学[M].21版.广州：世界图书出版公司，2003：97-130.
[44]	[45] Tomer Y,Davies TF.The genetic susceptibility to Graves' disease[J].Baillieres Clin Endocrinol Metab,1997,11(3):431-450.
[45]	[46] Rapoport B，Mclachlan SM.Graves disease：pathogenesis and treatment[M].Boston：Kluwer Academic Publishers，2000：307.
[46]	[47] 康增寿，戴维信，杜永昌.131I治疗儿童Graves甲亢安全、有效[J].国外医学:放射医学、核医学分册，2001，25(2)：149.
[47]	[48] 邓爱民，林延德，王国华.Graves病患者血清TRAb检测及临床意义[J].广东医学，2002，23(4)：398-399.
[48]	[49] 张文镇，李红，高永棣.血清TRAb放免检测在甲状腺疾病诊治中的价值[J].同位素，2001，14(2)：122-123.
[49]	[50] 彭盛梅.TRAb放免测定在Graves病人中的研究[J].广西医学,2000,22(6):1343.
[50]	[51] Zophel K，Wunderlich G，Kochj R，et al.Measurement of thyrotropin receptor antibodies(TRAb)with a second generation assay in patients with Graves disease[J].Nuklearmedizin，2000，39(4)：113-115.
[51]	[52] Takamura Y，Nakano K，Uruno T，et al.Changes in serum TSH receptor antibody(TRAb)values in patients with Graves'disease after total or subtotal thyroideetomy[J].Endocr J,2003，50(5)：595-601.

Cited By

Get Citation

XML

Article views (3374) PDF downloads (165)

Turn off MathJax

Article Contents

Abstract

References

Application of radioactive 131I in the treatment of Graves disease

Abstract

References

Catalog

Export File

Citation

Format

Content